Biomed AI- Artificial Intelligence for Drug Discovery

The cost to develop a new drug is every expensive, exceeding $2.6 billion. It normally takes over 15-20 years from the drug screening, lab testing, animal studies, Phase 1, Phase 1 and Phase 3 and the stringent FDA regulatory process. Recent advances in artificial intelligence (AI) may help to reverse this trend and accelerate and improve pharmaceutical research and development.

At Biomed, we have been applying the high-performance computing, and new frameworks for implementing deep neural networks (DNNs) in drug discovery.

Using training DNNs on transcriptional response data we can predict the pharmacological properties of small molecules (1) and biomarker development, (2) to the generation of novel chemistry.

One of medicinal chemistry related machine learning challenges is the selection of the representation of molecular structure to capture as many of the relevant chemical and biological features and come as close to reality as possible.

(Ref: Alex Zhavoronkov- Mol. Pharmaceutics 2018, 15, 10, 4311–4313)

Biomed team has sucessfully demonstrated the application of AI in developing new drug therapeutics for the treatment of neurodegenerative diseases. We plan to deploy our AI technology to optimize the Phase 2 and Phase 3 clinical trials of our drug NA-831 for the treatment and prevention of Alzheimer’s disease.